| Literature DB >> 24590260 |
Abstract
Microemulsions are fluid and isotropic formulations that have been widely studied as delivery systems for a variety of routes, including the skin. In spite of what the name suggests, microemulsions are nanocarriers, and their use as topical delivery systems derives from their multiple advantages compared to other dermatological formulations, such as ease of preparation, thermodynamic stability and penetration-enhancing properties. Composition, charge and internal structure have been reported as determinant factors for the modulation of drug release and cutaneous and transdermal transport. This manuscript aims at reviewing how these and other characteristics affect delivery and make microemulsions appealing for topical and transdermal administration, as well as how they can be modulated during the formulation design to improve the potential and efficacy of the final system.Entities:
Year: 2014 PMID: 24590260 PMCID: PMC3978525 DOI: 10.3390/pharmaceutics6010052
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Comparison of microemulsions with emulsions and nanoemulsions.
| Parameter | Microemulsion | Emulsion | Nanoemulsion |
|---|---|---|---|
| Type of dispersion | colloidal | coarse | colloidal |
| Internal phase size (μm) * | up to 0.15 | above 0.5 | up to 0.25 |
| Thermodynamic stability | stable | not stable | not stable |
| Formation | spontaneous | require energy | require energy |
| Composition | requires greater amounts of surfactant and co-surfactant combination | requires less surfactant | requires less surfactant |
|
| |||
| Consistency | fluid | fluid/semi-solid | fluid |
| Turbidity | transparent | milky | may vary |
* There is no specific value of particle size that represents a definitive cut-off point to differentiate these formulations. The values cited here serve only as guidelines based on papers published on this topic.
Examples of microemulsion composition and incorporated drugs used as transdermal delivery systems.
| Surfactant blend or surfactant/co-surfactant | Components of the oil phase | Drug | Reference |
|---|---|---|---|
| Aerosol OT/butanol | isopropyl palmitate | hydrophilic and lipophilic anesthetics | [ |
| Aerosol OT/Tween 85 | isopropyl myristate | cyclosporine A | [ |
| Aerosol OT | isopropyl myristate | 5-fluorouracil | [ |
| Polyoxyethylene (10) oleyl ether and1-hexanol | paraffin oil, isopropyl myristate or jojoba oil | sodium diclofenac | [ |
| polyoxyethylene (20) cetyl ether and Span 80, ethanol, isopropyl alcohol, and propanol | soybean oil | sodium diclofenac | [ |
| polyoxyethylene (10) dodecyl ether | tributyrin | progesterone | [ |
| polyoxyethylene (10) oleyl ether, propylene glycol | glycerides of caprylic and capric acid | lycopene | [ |
| polyoxyethylene (10) oleyl ether, propylene glycol, ethanol | monocaprylin | paclitaxel | [ |
| Tween 80 and Span 20/ethanol | isopropyl myristate | sodium nonivamide acetate | [ |
| Tween 80, ethanol, isopropanol or propylene glycol | eucalyptus oil | hydrocortisone | [ |
| Tween 80/propylene glycol | oleic acid, menthol | triptolide | [ |
| Tween 80/ethanol | isopropyl myristate, | diclofenac | [ |
| Tween 80 or Span 80/ ethanol or isopropanol | lecithin, oleic acid or isopropyl myristate | estradiol | [ |
| Tween 80/propylene glycol, ethanol, isopropanol | limonene, 1,8-cineole, α-terpineol | curcumin | [ |
| polysorbate 80/ medium-chain glyceride | isopropyl myristate | celecoxib | [ |
| PEG-8 glyceryl caprylate and caprate, diethylene glycol monoethyl ether (Transcutol P) | oleic acid | vinpocetine | [ |
| PEG-8 caprylic and capric glycerides, polyglyceryl-6 dioleate | isopropyl myristate | diclofenac diethylamine | [ |
| PEG-8 caprylic and capric glycerides/ polyglyceryl-6-dioleate | miglyol 812 | ascorbyl palmitate | [ |
| caprylocaproyl macrogol-8- glycerides, Transcutol P | oleic acid | terbinafine | [ |
| polyoxyl-35-castor oil, ethanol | oleoyl macrogol-6 glycerides EP | aceclofenac | [ |
| polyoxyl-35-castor oil, ethanol | oleic acid | penciclovir | [ |
| lecithin and linkers (sorbitan monooleate, sodium caprylate and caprylic acid) | isopropyl myristate | lidocaine | [ |
| lecithin/ | isopropyl myristate | tetracaine hydrochloride | [ |
| lecithin, isopropanol | isopropyl myristate, oleic acid | fluconazole | [ |
| glyceryl oleate/polyoxyl 40 fatty acid derivatives/tetraglycol | isopropyl myristate | lidocaine | [ |
| tocopheryl polyethylene glycol 1000 succinate | oleic acid, isopropyl myristate | temozolomide hexyl ester | [ |
| decylglucoside, propylene glycol, phytosphingosine | medium chain mono-diglycerides | α-tocopherol and lipoic acid | [ |
| decyl polyglucoside, lecithin, propylene glycol, 1,2-hexanediol | 1-decanol, 1-dodecanol | miconazole nitrate | [ |
| coco-glucoside, decylglucoside, lecithin | Labrafil M1944CS | 5-fluorouracil | [ |
Figure 1Microemulsion-related parameters influencing skin penetration and transdermal delivery of drugs and other active compounds. Depending on its physicochemical characteristics and system microstructure, a drug may be incorporated in the dispersed phase, dispersing medium and/or within the interface (at least partially). The term drug release was used here to address the process of a drug incorporated in any of these regions “leaving” the formulation, giving a measure of drug supply to the skin surface by the formulation. The term is generally used in the pharmaceutical literature. However, not every drug needs to be released, such as hydrophilic compounds dissolved in the dispersing aqueous phase. Hydrophobic drugs incorporated in non-polar domains must partition into stratum corneum, and some authors prefer the term “location exchange” for this process.